Cutler Group’s Viking Therapeutics VKTX Stock Holding History

Cutler Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$11K	Buy	+1,700	New	+$75.6K	﹤0.01%	1258
2023 Q2	–	Sell	-10,400	Closed	-$2K	–	4224
2023 Q1	$2K	Sell	10,400 -2,200	-17%	-$22.7K	﹤0.01%	3266
2022 Q4	$11K	Buy	+12,600	New	+$56.2K	﹤0.01%	2661
2022 Q2	–	Sell	-900	Closed	-$10K	–	5739
2022 Q1	$10K	Buy	+900	New	+$3.23K	﹤0.01%	3642
2020 Q2	–	Sell	-20,000	Closed	-$54K	–	4943
2020 Q1	$54K	Buy	+20,000	New	+$123K	﹤0.01%	1680
2019 Q1	–	Sell	-1,200	Closed	-$6K	–	4825
2018 Q4	$6K	Sell	1,200 -10,400	-90%	-$124K	﹤0.01%	2862
2018 Q3	$9K	Sell	11,600 -12,600	-52%	-$150K	﹤0.01%	2739
2018 Q2	$33K	Buy	+24,200	New	+$161K	﹤0.01%	1867

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Cutler Group's VKTX Position: Q1 2024 in Review

Cutler Group opened a new position in Viking Therapeutics (VKTX) in Q1 2024: 350 shares worth $28K. The stake represents 0.01% of the portfolio and ranks #902 among its holdings. This is a return to the name: Cutler Group previously reported a position in VKTX as recently as Q3 2023.

Cutler Group first reported a position in VKTX in Q2 2018 and has held it in 16 quarters since. The position peaked at $399K in Q3 2018. 375 funds tracked by Wall St. Rank hold VKTX as of Q1 2024.

Cutler Group held 350 shares of Viking Therapeutics worth $28K as of Q1 2024.
Viking Therapeutics was a new Cutler Group position in Q1 2024.
Viking Therapeutics made up 0.01% of Cutler Group's portfolio in Q1 2024, its #902 holding.
Cutler Group first reported a position in Viking Therapeutics in Q2 2018 and has held it in 16 quarters since.
Cutler Group's Viking Therapeutics position peaked at $399K in Q3 2018.
375 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.